Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9B

▤ Summary

Eli Lilly is striking a deal with Ascidian Therapeutics worth up to $1.9 billion to use its RNA exon editing platform for kidney disease programs. The agreement gives Lilly access to Ascidian’s technology for discovery, preclinical, clinical, manufacturing, and commercialization work. Ascidian will keep rights to use its platform for other kidney targets and for other partners. The transaction adds to Lilly’s aggressive deal-making as it continues to reinvest strong obesity-market revenues into pipeline growth.

▦ Linked Companies